Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 274.25B | 279.18B | 266.79B | 274.14B | 261.68B | 268.29B |
Gross Profit | 51.09B | 55.54B | 51.01B | 51.35B | 47.95B | 43.23B |
EBITDA | 47.11B | 51.36B | 49.05B | 45.17B | 41.61B | 37.37B |
Net Income | 24.12B | 26.93B | 25.04B | 24.62B | 20.86B | 17.93B |
Balance Sheet | ||||||
Total Assets | 477.72B | 491.09B | 483.92B | 456.04B | 434.73B | 415.54B |
Cash, Cash Equivalents and Short-Term Investments | 84.29B | 101.89B | 90.43B | 76.28B | 56.40B | 44.08B |
Total Debt | 30.54B | 40.49B | 30.00B | 20.00B | 0.00 | 0.00 |
Total Liabilities | 97.30B | 106.57B | 96.63B | 83.03B | 66.82B | 63.13B |
Stockholders Equity | 378.78B | 382.89B | 385.67B | 371.24B | 366.14B | 350.48B |
Cash Flow | ||||||
Free Cash Flow | 13.71B | 27.23B | 35.89B | 23.88B | 20.41B | 17.41B |
Operating Cash Flow | 13.71B | 40.41B | 42.47B | 35.56B | 37.04B | 29.56B |
Investing Cash Flow | 0.00 | -7.47B | -16.42B | -13.72B | -3.80B | -30.25B |
Financing Cash Flow | 0.00 | -17.89B | -12.22B | -2.22B | -9.78B | -8.63B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | ¥345.95B | 17.10 | 9.28% | 2.26% | 9.79% | 13.52% | |
75 Outperform | €401.25B | 24.14 | 6.74% | 1.67% | 11.50% | 2.66% | |
75 Outperform | ¥434.61B | 13.59 | 8.09% | 2.74% | 11.62% | 19.53% | |
74 Outperform | ¥386.60B | 13.79 | 10.64% | 2.59% | 7.67% | 33.08% | |
71 Outperform | ¥253.62B | 13.00 | 8.49% | 3.09% | 6.31% | 12.77% | |
70 Outperform | ¥283.90B | 28.23 | 3.85% | 7.73% | -17.17% | ||
63 Neutral | ¥378.70B | 15.68 | 6.91% | 2.47% | 4.65% | 10.69% |
Kamigumi Co., Ltd has announced a proposed amendment to its Articles of Incorporation to be discussed at the upcoming General Meeting of Shareholders. The amendment aims to clarify and expand the company’s business scope, including the manufacture of pharmaceuticals and cosmetics, and ownership of stock in other companies, reflecting its strategic plan for diversification and growth.
The most recent analyst rating on (JP:9364) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Kamigumi Co stock, see the JP:9364 Stock Forecast page.
Kamigumi Co., Ltd has announced a revision to its profit return policy, aiming for more aggressive shareholder returns under its Medium-Term Management Plan 2030. The company plans to increase its consolidated dividend payout ratio to 70% and purchase treasury stock worth approximately 65 billion yen to improve capital returns. Additionally, Kamigumi will raise its year-end dividend for FY2025 to 80 yen per share, marking a significant increase from the previous forecast, and plans further dividend increases in FY2026, reflecting its strong financial performance and commitment to shareholder value.
Kamigumi Co., Ltd has announced its Purpose, Long-Term Vision 2035, and Medium-Term Management Plan 2030, aiming to strengthen its position as an integrated logistics provider. The company plans to achieve ¥450,000 million in consolidated net sales by 2035 and has set financial goals for 2030, including ¥350,000 million in net sales and an 8.0% ROE. The plan focuses on increasing market share, establishing global revenue bases, expanding to meet new logistics needs, and enhancing operational efficiency through digital transformation.
Kamigumi Corporation reported a positive financial performance for the fiscal year ending March 31, 2025, with a 4.6% increase in operating revenues and an 8.2% rise in operating profit compared to the previous year. The company also announced an increase in dividends, reflecting its strong financial position and commitment to returning value to shareholders, while forecasting continued growth in the upcoming fiscal year.